CryoPort Inc (CYRX)

[robertmaxwell]

I've seen some rather odd posts over the past few days. Even though they're not directly related to Cyroport, so to speak, here are my thoughts:

1) The oral administration route isn't going anywhere. Period. While you may see an uptick in non-oral routes of administration commensurate with growth in gross number of pharmaceuticals available on market, orally-administered drugs will always have their place. (A bit of conjecture there at the end, but I'll take that bet 101 days out of 100.)

2) On dendritic cells: Might I ask why that's the "fulcrum security" of immunotherapy? I fundamentally disagree, but would love a cogent explanation as to why you all (I forget exactly who said it, but didn't see any disagreements) find that to be the case.

Lots of good data at AACR over the weekend. None directly affecting CYRX, but it's good to see industry-wide progress in new fields.